<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20231207050916&amp;utm_source=Chrome&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20231207050916&amp;utm_source=Chrome&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 07 Dec 2023 10:09:18 +0000</lastbuilddate>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Potential Expanded Applications of Minimally Invasive Cardiac Myectomy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057078/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):e237. doi: 10.1016/j.jacc.2023.10.012.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057078/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057078</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.012>10.1016/j.jacc.2023.10.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057078</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jing Fang</dc:creator>
<dc:creator>Yani Liu</dc:creator>
<dc:creator>Song Wan</dc:creator>
<dc:creator>Xiang Wei</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Potential Expanded Applications of Minimally Invasive Cardiac Myectomy</dc:title>
<dc:identifier>pmid:38057078</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.012</dc:identifier>
</item>
<item>
<title>Potential Expanded Applications of Minimally Invasive Cardiac Myectomy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057077/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):e235. doi: 10.1016/j.jacc.2023.09.829.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057077/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057077</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.829>10.1016/j.jacc.2023.09.829</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057077</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Ramdas G Pai</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Potential Expanded Applications of Minimally Invasive Cardiac Myectomy</dc:title>
<dc:identifier>pmid:38057077</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.829</dc:identifier>
</item>
<item>
<title>Role of Advanced Practice Providers in the Cardiac Intensive Care Unit Team</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057076/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2338-2342. doi: 10.1016/j.jacc.2023.08.061.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057076/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057076</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.061>10.1016/j.jacc.2023.08.061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057076</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Carolina D Tennyson</dc:creator>
<dc:creator>Margaret T Bowers</dc:creator>
<dc:creator>Allison W Dimsdale</dc:creator>
<dc:creator>Sharon M Dickinson</dc:creator>
<dc:creator>R Monica Sanford</dc:creator>
<dc:creator>Jordan D McKenzie-Solis</dc:creator>
<dc:creator>Hannah D Schimmer</dc:creator>
<dc:creator>Carlos L Alviar</dc:creator>
<dc:creator>Shashank S Sinha</dc:creator>
<dc:creator>Jason N Katz</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Role of Advanced Practice Providers in the Cardiac Intensive Care Unit Team</dc:title>
<dc:identifier>pmid:38057076</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.061</dc:identifier>
</item>
<item>
<title>Research Priorities in Critical Care Cardiology: JACC Expert Panel</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057075/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>Over the last several decades, the cardiac intensive care unit (CICU) has seen a substantial evolution in the patient population, comorbidities, and diagnoses. However, the generation of high-quality evidence to manage these complex and critically ill patients has been slow. Given the scarcity of clinical trials focused on critical care cardiology (CCC), CICU clinicians are often left to extrapolate from studies that either exclude or poorly represent the patient population admitted to CICUs....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2329-2337. doi: 10.1016/j.jacc.2023.09.828.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Over the last several decades, the cardiac intensive care unit (CICU) has seen a substantial evolution in the patient population, comorbidities, and diagnoses. However, the generation of high-quality evidence to manage these complex and critically ill patients has been slow. Given the scarcity of clinical trials focused on critical care cardiology (CCC), CICU clinicians are often left to extrapolate from studies that either exclude or poorly represent the patient population admitted to CICUs. The lack of high-quality evidence and limited guidance from society guidelines has led to significant variation in practice patterns for many of the most common CICU diagnoses. Several barriers, both common to critical care research and unique to CCC, have impeded progress. In this multinational perspective, we describe key areas of priority for CCC research, current challenges for investigation in the CICU, and essential elements of a path forward for the field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057075/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057075</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.828>10.1016/j.jacc.2023.09.828</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057075</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>P Elliott Miller</dc:creator>
<dc:creator>Kurt Huber</dc:creator>
<dc:creator>Erin A Bohula</dc:creator>
<dc:creator>Konstantin A Krychtiuk</dc:creator>
<dc:creator>Janine Pöss</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:creator>Guido Tavazzi</dc:creator>
<dc:creator>Michael A Solomon</dc:creator>
<dc:creator>Steen D Kristensen</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>ACC’s Critical Care Cardiology Member Section and the ESC Association for Acute CardioVascular Care</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Research Priorities in Critical Care Cardiology: JACC Expert Panel</dc:title>
<dc:identifier>pmid:38057075</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.828</dc:identifier>
</item>
<item>
<title>Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057074/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>Disparities by sex, race, socioeconomic status, and geography exist in diagnosis, treatment, and outcomes for people with lower extremity peripheral artery disease (PAD). PAD prevalence is similar in men and women, but women have more atypical symptoms and undergo lower extremity revascularization at older ages compared to men. People who are Black have an approximately 2-fold higher prevalence of PAD, compared to people who are White and have more atypical symptoms, greater mobility loss, less...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2312-2328. doi: 10.1016/j.jacc.2023.09.830.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Disparities by sex, race, socioeconomic status, and geography exist in diagnosis, treatment, and outcomes for people with lower extremity peripheral artery disease (PAD). PAD prevalence is similar in men and women, but women have more atypical symptoms and undergo lower extremity revascularization at older ages compared to men. People who are Black have an approximately 2-fold higher prevalence of PAD, compared to people who are White and have more atypical symptoms, greater mobility loss, less optimal medical care, and higher amputation rates. Although fewer data are available for other races, people with PAD who are Hispanic have higher amputation rates than White people. Rates of amputation also vary by geography in the United States, with the highest rates of amputation in the southeastern United States. To improve PAD outcomes, intentional actions to eliminate disparities are necessary, including clinician education, patient education with culturally appropriate messaging, improved access to high-quality health care, science focused on disparity elimination, and health policy changes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057074/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057074</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.830>10.1016/j.jacc.2023.09.830</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057074</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Mary M McDermott</dc:creator>
<dc:creator>Karen J Ho</dc:creator>
<dc:creator>Olamide Alabi</dc:creator>
<dc:creator>Michael H Criqui</dc:creator>
<dc:creator>Philip Goodney</dc:creator>
<dc:creator>Naomi Hamburg</dc:creator>
<dc:creator>Demetria M McNeal</dc:creator>
<dc:creator>Amy Pollak</dc:creator>
<dc:creator>Kim G Smolderen</dc:creator>
<dc:creator>Marc Bonaca</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:38057074</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.830</dc:identifier>
</item>
<item>
<title>Apixaban for Children With Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057073/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2310-2311. doi: 10.1016/j.jacc.2023.10.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057073/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057073</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.011>10.1016/j.jacc.2023.10.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057073</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Craig A Mullen</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Apixaban for Children With Heart Disease</dc:title>
<dc:identifier>pmid:38057073</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.011</dc:identifier>
</item>
<item>
<title>Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057072/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In this pediatric multinational, randomized trial, bleeding and thromboembolism were infrequent on apixaban and SOC. Apixaban PK data correlated well with adult trials that demonstrated efficacy. These results support the use of apixaban as an alternative to SOC for thromboprophylaxis in pediatric heart disease. (A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist [VKA] or Low Molecular Weight Heparin [LMWH] in Pediatric Subjects With Congenital or...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2296-2309. doi: 10.1016/j.jacc.2023.10.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Children with heart disease frequently require anticoagulation for thromboprophylaxis. Current standard of care (SOC), vitamin K antagonists or low-molecular-weight heparin, has significant disadvantages.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to describe safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of apixaban, an oral, direct factor Xa inhibitor, for prevention of thromboembolism in children with congenital or acquired heart disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Phase 2, open-label trial in children (ages, 28 days to &lt;18 years) with heart disease requiring thromboprophylaxis. Randomization 2:1 apixaban or SOC for 1 year with intention-to-treat analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">PRIMARY ENDPOINT: a composite of adjudicated major or clinically relevant nonmajor bleeding. Secondary endpoints: PK, pharmacodynamics, quality of life, and exploration of efficacy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 2017 to 2021, 192 participants were randomized, 129 apixaban and 63 SOC. Diagnoses included single ventricle (74%), Kawasaki disease (14%), and other heart disease (12%). One apixaban participant (0.8%) and 3 with SOC (4.8%) had major or clinically relevant nonmajor bleeding (% difference -4.0 [95% CI: -12.8 to 0.8]). Apixaban incidence rate for all bleeding events was nearly twice the rate of SOC (100.0 vs 58.2 per 100 person-years), driven by 12 participants with ≥4 minor bleeding events. No thromboembolic events or deaths occurred in either arm. Apixaban pediatric PK steady-state exposures were consistent with adult levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this pediatric multinational, randomized trial, bleeding and thromboembolism were infrequent on apixaban and SOC. Apixaban PK data correlated well with adult trials that demonstrated efficacy. These results support the use of apixaban as an alternative to SOC for thromboprophylaxis in pediatric heart disease. (A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist [VKA] or Low Molecular Weight Heparin [LMWH] in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation; NCT02981472).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057072/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057072</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.010>10.1016/j.jacc.2023.10.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057072</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>R Mark Payne</dc:creator>
<dc:creator>Kristin M Burns</dc:creator>
<dc:creator>Andrew C Glatz</dc:creator>
<dc:creator>Christoph Male</dc:creator>
<dc:creator>Andrea Donti</dc:creator>
<dc:creator>Leonardo R Brandão</dc:creator>
<dc:creator>Gunter Balling</dc:creator>
<dc:creator>Christina J VanderPluym</dc:creator>
<dc:creator>Frances Bu'Lock</dc:creator>
<dc:creator>Lazaros K Kochilas</dc:creator>
<dc:creator>Brigitte Stiller</dc:creator>
<dc:creator>James F Cnota</dc:creator>
<dc:creator>Otto Rahkonen</dc:creator>
<dc:creator>Asra Khan</dc:creator>
<dc:creator>Rachele Adorisio</dc:creator>
<dc:creator>Serban Stoica</dc:creator>
<dc:creator>Lindsay May</dc:creator>
<dc:creator>Jane C Burns</dc:creator>
<dc:creator>Jose Francisco K Saraiva</dc:creator>
<dc:creator>Kimberly E McHugh</dc:creator>
<dc:creator>John S Kim</dc:creator>
<dc:creator>Agustin Rubio</dc:creator>
<dc:creator>Nadia G Chía-Vazquez</dc:creator>
<dc:creator>Marcie R Meador</dc:creator>
<dc:creator>Joshua L Dyme</dc:creator>
<dc:creator>Alison M Reedy</dc:creator>
<dc:creator>Toni Ajavon-Hartmann</dc:creator>
<dc:creator>Praneeth Jarugula</dc:creator>
<dc:creator>Lauren E Carlson-Taneja</dc:creator>
<dc:creator>Donna Mills</dc:creator>
<dc:creator>Olivia Wheaton</dc:creator>
<dc:creator>Paul Monagle</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease</dc:title>
<dc:identifier>pmid:38057072</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.010</dc:identifier>
</item>
<item>
<title>Lipoprotein(a): More Than Just a Biomarker of Myocardial Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057071/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2292-2295. doi: 10.1016/j.jacc.2023.10.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057071/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057071</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.019>10.1016/j.jacc.2023.10.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057071</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Gilles Lambert</dc:creator>
<dc:creator>Kévin Chemello</dc:creator>
<dc:creator>Antonio Gallo</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a): More Than Just a Biomarker of Myocardial Fibrosis</dc:title>
<dc:identifier>pmid:38057071</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.019</dc:identifier>
</item>
<item>
<title>Association of Lipoprotein(a) Levels With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057070/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Elevated Lp(a) levels are linked to greater subclinical IMF, increased myocardial scar prevalence, and left atrial remodeling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2280-2291. doi: 10.1016/j.jacc.2023.10.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lipoprotein(a) (Lp[a]) has been identified as an emerging risk factor for adverse cardiovascular (CV) outcomes, including heart failure. However, the connections among Lp(a), myocardial fibrosis (interstitial and replacement), and cardiac remodeling as pathways to CV diseases remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study investigated the relationship between Lp(a) levels and myocardial fibrosis by cardiac magnetic resonance (CMR) T1 mapping and late gadolinium enhancement, as well as cardiac remodeling by cine CMR, in the MESA (Multi-Ethnic Study of Atherosclerosis) cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study included 2,040 participants with baseline Lp(a) measurements and T1 mapping for interstitial myocardial fibrosis (IMF) evaluation in 2010. Lp(a) was analyzed as a continuous variable (per log unit) and using clinical cutoff values of 30 and 50 mg/dL. Multivariate linear and logistic regression were used to assess the associations of Lp(a) with CMR measures of extracellular volume (ECV fraction [ECV%]), native T1 time, and myocardial scar, as well as parameters of cardiac remodeling, in 2,826 participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Higher Lp(a) levels were associated with increased ECV% (per log-unit Lp[a]; β = 0.2%; P = 0.007) and native T1 time (per log-unit Lp[a]; β = 4%; P &lt; 0.001). Similar relationships were observed between elevated Lp(a) levels and a higher risk of clinically significant IMF defined by prognostic thresholds per log-unit Lp(a) of ECV% (OR: 1.20; 95% CI: 1.04-1.43) and native T1 (OR: 1.2; 95% CI: 1.1-1.4) equal to 30% and 955 ms, respectively. Clinically used Lp(a) cutoffs (30 and 50 mg/dL) were associated with greater prevalence of myocardial scar (OR: 1.85; 95% CI: 1.1-3.2 and OR: 1.9; 95% CI: 1.1-3.4, respectively). Finally, higher Lp(a) levels were associated with left atrial enlargement and dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Elevated Lp(a) levels are linked to greater subclinical IMF, increased myocardial scar prevalence, and left atrial remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057070/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057070</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.016>10.1016/j.jacc.2023.10.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057070</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Omar Chehab</dc:creator>
<dc:creator>Ashkan Abdollahi</dc:creator>
<dc:creator>Seamus P Whelton</dc:creator>
<dc:creator>Colin O Wu</dc:creator>
<dc:creator>Bharath Ambale-Venkatesh</dc:creator>
<dc:creator>Wendy S Post</dc:creator>
<dc:creator>David A Bluemke</dc:creator>
<dc:creator>Michael Y Tsai</dc:creator>
<dc:creator>João A C Lima</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Lipoprotein(a) Levels With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis</dc:title>
<dc:identifier>pmid:38057070</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.016</dc:identifier>
</item>
<item>
<title>Lipoprotein(a), Peripheral Artery Disease, and Abdominal Aortic Aneurysm: The Next Frontier or Another Risk Enhancer?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2277-2279. doi: 10.1016/j.jacc.2023.10.015.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057069</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.015>10.1016/j.jacc.2023.10.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057069</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:creator>Alexander E Sullivan</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a), Peripheral Artery Disease, and Abdominal Aortic Aneurysm: The Next Frontier or Another Risk Enhancer?</dc:title>
<dc:identifier>pmid:38057069</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.015</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057068/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: High Lp(a) levels increased risk of PAD, AAA, and MALE by 2- to 3-fold in the general population, opening opportunities for prevention given future Lp(a)-lowering therapies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2265-2276. doi: 10.1016/j.jacc.2023.10.009.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lp(a) (lipoprotein[a])-lowering therapy to reduce cardiovascular disease is under investigation in phase 3 clinical trials. High Lp(a) may be implicated in peripheral artery disease (PAD), abdominal aortic aneurysms (AAAs), and major adverse limb events (MALE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors investigated the association of high Lp(a) levels and corresponding LPA genotypes with risk of PAD, AAA, and MALE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors included 108,146 individuals from the Copenhagen General Population Study. During follow-up, 2,450 developed PAD, and 1,251 AAAs. Risk of MALE was assessed in individuals with PAD at baseline and replicated in the Copenhagen City Heart Study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Higher Lp(a) was associated with a stepwise increase in risk of PAD and AAA (P for trend &lt;0.001). For individuals with Lp(a) levels ≥99th (≥143 mg/dL, ≥307 nmol/L) vs &lt;50th percentile (≤9 mg/dL, ≤17 nmol/L), multivariable-adjusted HRs were 2.99 (95% CI: 2.09-4.30) for PAD and 2.22 (95% CI: 1.21-4.07) for AAA. For individuals with PAD, the corresponding incidence rate ratio for MALE was 3.04 (95% CI: 1.55-5.98). Per 50 mg/dL (105 nmol/L) genetically higher Lp(a) risk ratios were 1.39 (95% CI: 1.24-1.56) for PAD and 1.21 (95% CI: 1.01-1.44) for AAA, consistent with observational risk ratios of 1.33 (95% CI: 1.24-1.43) and 1.27 (95% CI: 1.15-1.41), respectively. In women smokers aged 70 to 79 years with Lp(a) &lt;50th and ≥99th percentile, absolute 10-year risks of PAD were 8% and 21%, and equivalent risks in men 11% and 29%, respectively. For AAA, corresponding risks were 2% and 4% in women, and 5% and 12% in men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: High Lp(a) levels increased risk of PAD, AAA, and MALE by 2- to 3-fold in the general population, opening opportunities for prevention given future Lp(a)-lowering therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057068/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057068</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.009>10.1016/j.jacc.2023.10.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057068</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Peter E Thomas</dc:creator>
<dc:creator>Signe Vedel-Krogh</dc:creator>
<dc:creator>Sune F Nielsen</dc:creator>
<dc:creator>Børge G Nordestgaard</dc:creator>
<dc:creator>Pia R Kamstrup</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events</dc:title>
<dc:identifier>pmid:38057068</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.009</dc:identifier>
</item>
<item>
<title>Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057067/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2262-2264. doi: 10.1016/j.jacc.2023.10.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057067/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057067</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.020>10.1016/j.jacc.2023.10.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057067</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Abdul Mannan Khan Minhas</dc:creator>
<dc:creator>Carl E Orringer</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?</dc:title>
<dc:identifier>pmid:38057067</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.020</dc:identifier>
</item>
<item>
<title>Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057066/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2251-2261. doi: 10.1016/j.jacc.2023.10.007.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Inclisiran is a small interfering RNA agent to lower low-density lipoprotein cholesterol.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This post hoc analysis comprised patients treated with 300 mg inclisiran sodium or placebo in the completed (ORION-1, -3, -5, -9, -10, and -11) and ongoing (ORION-8) trials. Exposure-adjusted incidence rates and Kaplan-Meier estimates of cumulative incidence of reported treatment-emergent adverse events (TEAE), abnormal laboratory measurements, and incidence of antidrug antibodies were analyzed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This analysis included 3,576 patients treated with inclisiran for up to 6 years and 1,968 patients treated with placebo for up to 1.5 years, with 9,982.1 and 2,647.7 patient-years of exposure, respectively. Baseline characteristics were balanced between groups. Kaplan-Meier analyses showed that TEAEs that were serious or led to discontinuation; hepatic, muscle, and kidney events; incident diabetes; and elevations of creatine kinase or creatinine accrued at a comparable rate between groups for up to 1.5 years, with similar trends continuing for inclisiran beyond this period. Numerically fewer major cardiovascular events reported as TEAEs occurred with inclisiran during this period. Treatment-induced antidrug antibodies were uncommon with inclisiran (4.6%), with few of these persistent (1.4%) and not associated with greater incidence of TEAEs leading to study drug discontinuation or serious TEAEs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057066/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057066</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.007>10.1016/j.jacc.2023.10.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057066</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>R Scott Wright</dc:creator>
<dc:creator>Wolfgang Koenig</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Frederick J Raal</dc:creator>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:creator>Anastasia Lesogor</dc:creator>
<dc:creator>Pierre Maheux</dc:creator>
<dc:creator>Christian Stratz</dc:creator>
<dc:creator>Xiao Zang</dc:creator>
<dc:creator>Kausik K Ray</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials</dc:title>
<dc:identifier>pmid:38057066</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.007</dc:identifier>
</item>
<item>
<title>Choroid plexus mast cells drive tumor-associated hydrocephalus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38056463/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>Tumor-associated hydrocephalus (TAH) is a common and lethal complication of brain metastases. Although other factors beyond mechanical obstructions have been suggested, the exact mechanisms are unknown. Using single-nucleus RNA sequencing and spatial transcriptomics, we find that a distinct population of mast cells locate in the choroid plexus and dramatically increase during TAH. Genetic fate tracing and intracranial mast-cell-specific tryptase knockout showed that choroid plexus mast cells...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 28:S0092-8674(23)01182-0. doi: 10.1016/j.cell.2023.11.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Tumor-associated hydrocephalus (TAH) is a common and lethal complication of brain metastases. Although other factors beyond mechanical obstructions have been suggested, the exact mechanisms are unknown. Using single-nucleus RNA sequencing and spatial transcriptomics, we find that a distinct population of mast cells locate in the choroid plexus and dramatically increase during TAH. Genetic fate tracing and intracranial mast-cell-specific tryptase knockout showed that choroid plexus mast cells (CPMCs) disrupt cilia of choroid plexus epithelia via the tryptase-PAR2-FoxJ1 pathway and consequently increase cerebrospinal fluid production. Mast cells are also found in the human choroid plexus. Levels of tryptase in cerebrospinal fluid are closely associated with clinical severity of TAH. BMS-262084, an inhibitor of tryptase, can cross the blood-brain barrier, inhibit TAH in vivo, and alleviate mast-cell-induced damage of epithelial cilia in a human pluripotent stem-cell-derived choroid plexus organoid model. Collectively, we uncover the function of CPMCs and provide an attractive therapy for TAH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38056463/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38056463</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.001>10.1016/j.cell.2023.11.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38056463</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Yiye Li</dc:creator>
<dc:creator>Can Di</dc:creator>
<dc:creator>Shijian Song</dc:creator>
<dc:creator>Yubo Zhang</dc:creator>
<dc:creator>Yiwen Lu</dc:creator>
<dc:creator>Jianyou Liao</dc:creator>
<dc:creator>Bingxi Lei</dc:creator>
<dc:creator>Jian Zhong</dc:creator>
<dc:creator>Kaihua Guo</dc:creator>
<dc:creator>Nu Zhang</dc:creator>
<dc:creator>Shicheng Su</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Choroid plexus mast cells drive tumor-associated hydrocephalus</dc:title>
<dc:identifier>pmid:38056463</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.001</dc:identifier>
</item>
<item>
<title>An enzyme that selectively S-nitrosylates proteins to regulate insulin signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38056462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>Acyl-coenzyme A (acyl-CoA) species are cofactors for numerous enzymes that acylate thousands of proteins. Here, we describe an enzyme that uses S-nitroso-CoA (SNO-CoA) as its cofactor to S-nitrosylate multiple proteins (SNO-CoA-assisted nitrosylase, SCAN). Separate domains in SCAN mediate SNO-CoA and substrate binding, allowing SCAN to selectively catalyze SNO transfer from SNO-CoA to SCAN to multiple protein targets, including the insulin receptor (INSR) and insulin receptor substrate 1 (IRS1)....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 30:S0092-8674(23)01226-6. doi: 10.1016/j.cell.2023.11.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Acyl-coenzyme A (acyl-CoA) species are cofactors for numerous enzymes that acylate thousands of proteins. Here, we describe an enzyme that uses S-nitroso-CoA (SNO-CoA) as its cofactor to S-nitrosylate multiple proteins (SNO-CoA-assisted nitrosylase, SCAN). Separate domains in SCAN mediate SNO-CoA and substrate binding, allowing SCAN to selectively catalyze SNO transfer from SNO-CoA to SCAN to multiple protein targets, including the insulin receptor (INSR) and insulin receptor substrate 1 (IRS1). Insulin-stimulated S-nitrosylation of INSR/IRS1 by SCAN reduces insulin signaling physiologically, whereas increased SCAN activity in obesity causes INSR/IRS1 hypernitrosylation and insulin resistance. SCAN-deficient mice are thus protected from diabetes. In human skeletal muscle and adipose tissue, SCAN expression increases with body mass index and correlates with INSR S-nitrosylation. S-nitrosylation by SCAN/SNO-CoA thus defines a new enzyme class, a unique mode of receptor tyrosine kinase regulation, and a revised paradigm for NO function in physiology and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38056462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38056462</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.009>10.1016/j.cell.2023.11.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38056462</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Hua-Lin Zhou</dc:creator>
<dc:creator>Zachary W Grimmett</dc:creator>
<dc:creator>Nicholas M Venetos</dc:creator>
<dc:creator>Colin T Stomberski</dc:creator>
<dc:creator>Zhaoxia Qian</dc:creator>
<dc:creator>Precious J McLaughlin</dc:creator>
<dc:creator>Puneet K Bansal</dc:creator>
<dc:creator>Rongli Zhang</dc:creator>
<dc:creator>James D Reynolds</dc:creator>
<dc:creator>Richard T Premont</dc:creator>
<dc:creator>Jonathan S Stamler</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An enzyme that selectively S-nitrosylates proteins to regulate insulin signaling</dc:title>
<dc:identifier>pmid:38056462</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.009</dc:identifier>
</item>
<item>
<title>Mosaic loss of chromosome Y and cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057442/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Dec 6. doi: 10.1038/s41569-023-00976-x. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057442/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38057442</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00976-x>10.1038/s41569-023-00976-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057442</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Soichi Sano</dc:creator>
<dc:creator>Kenneth Walsh</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Mosaic loss of chromosome Y and cardiovascular disease</dc:title>
<dc:identifier>pmid:38057442</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00976-x</dc:identifier>
</item>
<item>
<title>Female Patient Presenting With Increasing Pedal Edema</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38055286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 6. doi: 10.1001/jamacardio.2023.4495. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38055286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38055286</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4495>10.1001/jamacardio.2023.4495</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38055286</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Vinesh Appadurai</dc:creator>
<dc:creator>Neela Thangada</dc:creator>
<dc:creator>Akhil Narang</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Female Patient Presenting With Increasing Pedal Edema</dc:title>
<dc:identifier>pmid:38055286</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4495</dc:identifier>
</item>
<item>
<title>Sudden ST-Segment Changes in a Critically Ill Patient</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38055285/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 6. doi: 10.1001/jamacardio.2023.4490. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38055285/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38055285</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4490>10.1001/jamacardio.2023.4490</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38055285</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jessica M Hong</dc:creator>
<dc:creator>Ching Zhu</dc:creator>
<dc:creator>Marcella C Press</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sudden ST-Segment Changes in a Critically Ill Patient</dc:title>
<dc:identifier>pmid:38055285</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4490</dc:identifier>
</item>
<item>
<title>Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38055247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Results of this cohort study suggest that PCE performed well overall but had poorer performance in both BM and WM participants compared with female participants regardless of race in the REGARDS cohort. Removal of race or the addition of SDOH did not improve model performance in any subgroup.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 6. doi: 10.1001/jamacardio.2023.4520. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Use of race-specific risk prediction in clinical medicine is being questioned. Yet, the most commonly used prediction tool for atherosclerotic cardiovascular disease (ASCVD)-pooled cohort risk equations (PCEs)-uses race stratification.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To quantify the incremental value of race-specific PCEs and determine whether adding social determinants of health (SDOH) instead of race improves model performance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Included in this analysis were participants from the biracial Reasons for Geographic and Racial Differences in Stroke (REGARDS) prospective cohort study. Participants were aged 45 to 79 years, without ASCVD, and with low-density lipoprotein cholesterol level of 70 to 189 mg/dL or non-high-density lipoprotein cholesterol level of 100 to 219 mg/dL at baseline during the period of 2003 to 2007. Participants were followed up to 10 years for incident ASCVD, including myocardial infarction, coronary heart disease death, and fatal and nonfatal stroke. Study data were analyzed from July 2022 to February 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME/MEASURES: Discrimination (C statistic, Net Reclassification Index [NRI]), and calibration (plots, Nam D'Agostino test statistic comparing observed to predicted events) were assessed for the original PCE, then for a set of best-fit, race-stratified equations including the same variables as in the PCE (model C), best-fit equations without race stratification (model D), and best-fit equations without race stratification but including SDOH as covariates (model E).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 11 638 participants (mean [SD] age, 61.8 [8.3] years; 6764 female [58.1%]) from the REGARDS cohort. Across all strata (Black female, Black male, White female, and White male participants), C statistics did not change substantively compared with model C (Black female, 0.71; 95% CI, 0.68-0.75; Black male, 0.68; 95% CI, 0.64-0.73; White female, 0.77; 95% CI, 0.74-0.81; White male, 0.68; 95% CI, 0.64-0.71), in model D (Black female, 0.71; 95% CI, 0.67-0.75; Black male, 0.68; 95% CI, 0.63-0.72; White female, 0.76; 95% CI, 0.73-0.80; White male, 0.68; 95% CI, 0.65-0.71), or in model E (Black female, 0.72; 95% CI, 0.68-0.76; Black male, 0.68; 95% CI, 0.64-0.72; White female, 0.77; 95% CI, 0.74-0.80; White male, 0.68; 95% CI, 0.65-0.71). Comparing model D with E using the NRI showed a net percentage decline in the correct assignment to higher risk for male but not female individuals. The Nam D'Agostino test was not significant for all race-sex strata in each model series, indicating good calibration in all groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Results of this cohort study suggest that PCE performed well overall but had poorer performance in both BM and WM participants compared with female participants regardless of race in the REGARDS cohort. Removal of race or the addition of SDOH did not improve model performance in any subgroup.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38055247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38055247</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4520>10.1001/jamacardio.2023.4520</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38055247</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Arnab K Ghosh</dc:creator>
<dc:creator>Sara Venkatraman</dc:creator>
<dc:creator>Michael G Nanna</dc:creator>
<dc:creator>Monika M Safford</dc:creator>
<dc:creator>Lisandro D Colantonio</dc:creator>
<dc:creator>Todd M Brown</dc:creator>
<dc:creator>Laura C Pinheiro</dc:creator>
<dc:creator>Eric D Peterson</dc:creator>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:creator>Madeline R Sterling</dc:creator>
<dc:creator>Orysya Soroka</dc:creator>
<dc:creator>Musarrat Nahid</dc:creator>
<dc:creator>Samprit Banerjee</dc:creator>
<dc:creator>Parag Goyal</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification</dc:title>
<dc:identifier>pmid:38055247</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4520</dc:identifier>
</item>
<item>
<title>Multifaceted Strategy Based on Automated Text Messaging After a Recent Heart Failure Admission: The MESSAGE-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38055237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: An intensive telemonitoring strategy applied in the vulnerable period after an HF admission was feasible, well-accepted, and increased scores of HF self-care but did not translate to reductions in NT-proBNP levels nor improvement in a composite hierarchical clinical outcome.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 6. doi: 10.1001/jamacardio.2023.4501. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Readmissions after an index heart failure (HF) hospitalization are a major contemporary health care problem.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the feasibility and efficacy of an intensive telemonitoring strategy in the vulnerable period after an HF hospitalization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted in 30 HF clinics in Brazil. Patients with left ventricular ejection fraction less than 40% and access to mobile phones were enrolled up to 30 days after an HF admission. Data were collected from July 2019 to July 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Participants were randomly assigned to a telemonitoring strategy or standard care. The telemonitoring group received 4 daily short message service text messages to optimize self-care, active engagement, and early intervention. Red flags based on feedback messages triggered automatic diuretic adjustment and/or a telephone call from the health care team.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was change in N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline to 180 days. A hierarchical win-ratio analysis incorporating blindly adjudicated clinical events (cardiovascular deaths and HF hospitalization) and variation in NT-proBNP was also performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 699 included patients, 460 (65.8%) were male, and the mean (SD) age was 61.2 (14.5) years. A total of 352 patients were randomly assigned to the telemonitoring strategy and 347 to standard care. Satisfaction with the telemonitoring strategy was excellent (net promoting score at 180 days, 78.5). HF self-care increased significantly in the telemonitoring group compared with the standard care group (score difference at 30 days, -2.21; 95% CI, -3.67 to -0.74; P = .001; score difference at 180 days, -2.08; 95% CI, -3.59 to -0.57; P = .004). Variation of NT-proBNP was similar in the telemonitoring group compared with the standard care group (telemonitoring: baseline, 2593 pg/mL; 95% CI, 2314-2923; 180 days, 1313 pg/mL; 95% CI, 1117-1543; standard care: baseline, 2396 pg/mL; 95% CI, 2122-2721; 180 days, 1319 pg/mL; 95% CI, 1114-1564; ratio of change, 0.92; 95% CI, 0.77-1.11; P = .39). Hierarchical analysis of the composite outcome demonstrated a similar number of wins in both groups (telemonitoring, 49 883 of 122 144 comparisons [40.8%]; standard care, 48 034 of 122 144 comparisons [39.3%]; win ratio, 1.04; 95% CI, 0.86-1.26).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: An intensive telemonitoring strategy applied in the vulnerable period after an HF admission was feasible, well-accepted, and increased scores of HF self-care but did not translate to reductions in NT-proBNP levels nor improvement in a composite hierarchical clinical outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04062461.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38055237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38055237</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4501>10.1001/jamacardio.2023.4501</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38055237</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Luis E Rohde</dc:creator>
<dc:creator>Marciane M Rover</dc:creator>
<dc:creator>Conrado R Hoffmann Filho</dc:creator>
<dc:creator>Eneida Rejane Rabelo-Silva</dc:creator>
<dc:creator>Odilson M Silvestre</dc:creator>
<dc:creator>Silvia M Martins</dc:creator>
<dc:creator>Luiz C S Passos</dc:creator>
<dc:creator>José A de Figueiredo Neto</dc:creator>
<dc:creator>Luiz C Danzmann</dc:creator>
<dc:creator>Fábio S Silveira</dc:creator>
<dc:creator>Cezar Eumann Mesas</dc:creator>
<dc:creator>Mauro E Hernandes</dc:creator>
<dc:creator>Lidia Z Moura</dc:creator>
<dc:creator>Marcus V Simões</dc:creator>
<dc:creator>Luiz E F Ritt</dc:creator>
<dc:creator>Fábio Akio Nishijuka</dc:creator>
<dc:creator>Eduardo G Bertoldi</dc:creator>
<dc:creator>Frederico T C Dall Orto</dc:creator>
<dc:creator>Ellen Hettwer Magedanz</dc:creator>
<dc:creator>Ricardo Mourilhe-Rocha</dc:creator>
<dc:creator>Miguel M Fernandes-Silva</dc:creator>
<dc:creator>Almir Sergio Ferraz</dc:creator>
<dc:creator>Pedro Schwartzmann</dc:creator>
<dc:creator>Fábio M de Castilho</dc:creator>
<dc:creator>Antonio Carlos Pereira Barretto</dc:creator>
<dc:creator>Edval Gomes Dos Santos Júnior</dc:creator>
<dc:creator>Paulo Roberto Nogueira</dc:creator>
<dc:creator>Manoel Canesin</dc:creator>
<dc:creator>Luis Beck-da-Silva</dc:creator>
<dc:creator>Maísa de Carvalho Silva</dc:creator>
<dc:creator>Mario Sergio Adolfi Júnior</dc:creator>
<dc:creator>Renato H N Santos</dc:creator>
<dc:creator>Amanda Ferreira</dc:creator>
<dc:creator>Danielle Pereira</dc:creator>
<dc:creator>Leticia Lopes</dc:creator>
<dc:creator>Flávia C S Kojima</dc:creator>
<dc:creator>Viviane Campos</dc:creator>
<dc:creator>Pedro G M de Barros E Silva</dc:creator>
<dc:creator>Mariana Blacher</dc:creator>
<dc:creator>Alexandre B Cavalcanti</dc:creator>
<dc:creator>Felix Ramires</dc:creator>
<dc:creator>MESSAGE-HF Investigators</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Multifaceted Strategy Based on Automated Text Messaging After a Recent Heart Failure Admission: The MESSAGE-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38055237</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4501</dc:identifier>
</item>
<item>
<title>Race, Racism, and Risk-Implications of Social Determinants of Health in Cardiovascular Disease Prediction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38055236/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207050916&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 6. doi: 10.1001/jamacardio.2023.4529. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38055236/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207050916&v=2.17.9.post6+86293ac">38055236</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4529>10.1001/jamacardio.2023.4529</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38055236</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Race, Racism, and Risk-Implications of Social Determinants of Health in Cardiovascular Disease Prediction</dc:title>
<dc:identifier>pmid:38055236</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4529</dc:identifier>
</item>





























</channel>
</rss>